KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

Abstract Background Although immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients with non‐small cell lung carcinoma (NSCLC), the potential association between Kirsten rat sarcoma viral oncogene ho...

Full description

Bibliographic Details
Main Authors: Chengming Liu, Sufei Zheng, Zhanyu Wang, Sihui Wang, Xinfeng Wang, Lu Yang, Haiyan Xu, Zheng Cao, Xiaoli Feng, Qi Xue, Yan Wang, Nan Sun, Jie He
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Cancer Communications
Subjects:
KRAS‐G12D
non‐small cell lung carcinoma
immunotherapy
PD‐L1
tumor‐infiltrating lymphocyte
chemo‐immunotherapy
Online Access:https://doi.org/10.1002/cac2.12327

Similar Items

Similar Items